AbbVie Provides Update on Phase 2 Results for Emraclidine in ...

Nov 11, 2024 · EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint; Emraclidine was well-tolerated with an adverse event profile consistent with Phase …

CouponFollow Extension

12%
OFF

AbbVie's Closely Watched Schizophrenia Drug Fails Two Studies, …

1 week from now

6 days ago · AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers …

reuters.com

$8
OFF

AbbVie Shares Fall Premarket After Schizophrenia Drug Study Failure

1 week from now

6 days ago · Emraclidine was a main focus of AbbVie's $8.7 billion acquisition of Cerevel, which closed earlier this year. Another Cerevel drug candidate, tavapadon, has shown promise in …

marketscreener.com

11%
OFF

AbbVie Stock Falls 11% In A Month: Should You Buy The Dip?

1 week from now

3 days ago · ABBV Stock Valuation. Image Source: Zacks Investment Research. The Zacks Consensus Estimate for 2024 earnings has risen from $10.87 to $10.93 per share over the …

zacks.com

11%
OFF

AbbVie Stock Falls 11% In A Month: Should You Buy The Dip?

1 week from now

2 days ago · November 15, 2024 — 10:08 am EST. Written by Kinjel Shah for Zacks ->. AbbVie ’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. …

nasdaq.com

11%
OFF

AbbVie Stock Falls 11% In A Month: Should You Buy The Dip?

1 week from now

2 days ago · AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback.In November, AbbVie announced that two registration-enabling phase II …

yahoo.com